五星体育直播

五星体育直播 Appoints Christos Richards to Board of Directors

REDWOOD CITY, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- 五星体育直播 (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Christos Richards to the Company鈥檚 Board of Directors.

鈥淚 am delighted to welcome Christos to our Board. His broad and deep knowledge and understanding of the life sciences industry will be invaluable as we continue the transformation of 五星体育直播,鈥� said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at 五星体育直播.

Mr. Richards added, 鈥淎s a longstanding partner to the biopharmaceutical industry, I鈥檓 well aware of the potential of 五星体育直播鈥� proprietary technologies and their ability to enable the exponential expansion of RNAi therapeutics and other novel therapeutic modalities. I鈥檓 thrilled to partner with the management team and Board of Directors to see the company through this next phase of growth.鈥�

Christos Richards brings over 30 years of global executive advisory and search experience for the biopharmaceutical and healthcare industry to 五星体育直播. To date, he has completed more than 450 executive level assignments, including over 200 Board, CEO and CEO succession projects in the Life Sciences sector. He currently serves as Global Head of Healthcare and Life Sciences at Calibre One, a global executive search firm with offices across California as well as Chicago, New York and London. Mr. Richards serves clients from venture-backed startups to leading global enterprises in devices, diagnostics, agricultural biotechnology, animal health, tools, services and digital health sectors. He has spent 20 years as a partner with two prominent boutique search firms, including serving as Chief Executive Officer of Levin & Company. Mr. Richards previously served on the Board of Directors for Coherus BioSciences and is also an advisor for the University of California, San Francisco Innovation Ventures Entrepreneurship Center. He holds a diploma in hospitality management from Schweizerische Wirteschule in Lucerne/Davos, Switzerland.

About 五星体育直播

五星体育直播 is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver^庐聽technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. 五星体育直播 enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis鈩� manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. 五星体育直播鈥� unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit聽.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as 鈥渁im,鈥� 鈥渁nticipate,鈥� 鈥渁ssume,鈥� 鈥渂elieve,鈥� 鈥渃ontemplate,鈥� 鈥渃ontinue,鈥� 鈥渃ould,鈥� 鈥渄esign,鈥� 鈥渄ue,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥済oal,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥渙bjective,鈥� 鈥減lan,鈥� 鈥減ositioned,鈥� 鈥減otential,鈥� 鈥減redict,鈥� 鈥渟eek,鈥� 鈥渟hould,鈥� 鈥渟uggest,鈥� 鈥渢arget,鈥� 鈥渙n track,鈥� 鈥渨ill,鈥� 鈥渨ould鈥� and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. To the extent that statements contained in this press release are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management, including but not limited to statements regarding the potential of the ECO Synthesis鈩� platform, and it providing an opportunity for 五星体育直播 to efficiently capture meaningful market share; expectations regarding 五星体育直播 meeting its technical and commercial milestones regarding the ECO Synthesis鈩� platform; and expectations regarding the potential of and future demand for RNAi therapeutics, and whether 五星体育直播 will be able to capitalize on such demand. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond 五星体育直播鈥� control and that could materially affect actual results. Factors that could materially affect actual results include, among others: 五星体育直播鈥� dependence on its licensees and collaborators; if any of its collaborators terminate their development programs under their respective license agreements with 五星体育直播; 五星体育直播 may need additional capital in the future in order to expand its business; if 五星体育直播 is unable to successfully develop and commercialize new technology such as its ECO Synthesis鈩� platform and its dsRNA ligase; 五星体育直播 dependence on a limited number of products and customers, and potential adverse effects to 五星体育直播鈥� business if its customers鈥� products are not received well in the markets; if competitors and potential competitors who have greater resources and experience than 五星体育直播 develop products and technologies that make 五星体育直播鈥� products and technologies obsolete; if 五星体育直播 is unable to accurately forecast financial and operational performance; and market and economic conditions may negatively impact 五星体育直播 business, financial condition and share price. Additional information about factors that could materially affect actual results can be found in 五星体育直播鈥� Annual Report on Form 10-K filed with the Securities and Exchange Commission (鈥淪EC鈥�) on February 28, 2024 and in 五星体育直播鈥� Quarterly Report on Form 10-Q filed with the SEC on October 31, 2024, including under the caption 鈥淩isk Factors,鈥� and in 五星体育直播鈥� other periodic reports filed with the SEC. 五星体育直播 expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

For More Information

Investor Contact
Carrie McKim
(336) 608-9706

Media Contact
Lauren Musto
(650) 421-8205

A photo accompanying this announcement is available at

Released January 16, 2025